Investment Considerations PaxMedica recently announced positive top line results from its PAX-101 Phase 3 African Sleeping Sickness Study, paving the way for an expected New Drug Application filing in 2024. The company granted exclusive pharmacy distribution for PAX-101 to Vox Nova LLC, the first purpose-built limited distribution specialty pharmacy benefit manager for people with ASD. … Continue reading “PaxMedica Inc. (OTC: PXMD)”
Symbol | Release | Time | Source |
---|---|---|---|
{{ release.qmtopics.qmsymbol[0].symbol }} | {{ release.headline }} | {{ release.datetime | amDateFormat:'hh:mm A'}} | {{ release.source }} |
SmallCapRelations is part of the IBN (InvestorBrandNetwork).